White Lauren
Known title: Chief Financial OfficerCIK: 0001864430
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
Transaction History
| SPTX | ▼ Sell | Other | 6,702 | — | 5/4/2026 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 2,250 | — | 8/30/2023 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 661 | $2K | 8/30/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 26,000 | $0 | 2/13/2023 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 1,301 | $10K | 1/30/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 3,750 | — | 1/30/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 3,750 | — | 5/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data
Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.
Seaport Therapeutics Gains Analyst Attention Ahead of ECNP Data. Seaport Therapeutics has attracted new analyst coverage, with Canaccord Genuity and HC Wainwright both issuing price targets of $28 and $50 respectively. The company will present additional pharmacokinetic data from its Phase 1 GlyphAgo trial at the ECNP Congress in October. These developments add fresh information for investors to assess the drug’s progress. The stock remains near its 52‑week low, with a support level around $17.79.